Default company panoramic image
Ccf982ce a415 493f aeeb 0a8fce3f4f64

re:Viral Ltd

reViral, a UK start-up focused on development of novel therapies for respiratory syncytial virus, a major untapped market. reViral has been founded by the ...

  • Stage Product In Development
  • Industry Biotechnology
  • Location GBK Restaurants Ltd, Lindsey Street, London, England, United Kingdom
  • Currency GBP
  • Founded January 2011
  • Employees 5

Company Summary

reViral, a UK start-up focused on development of novel therapies for respiratory syncytial virus, a major untapped market. reViral has been founded by the drug discovery team of Arrow Therapeutics, with over 10 yrs experience in RSV therapies. RSV remains an untreated disease in majority of patient groups and Pharma companies are proactively seeking to buy programs/drugs for RSV. RSV assets can create high value exits for investors in 3-5 yrs.

Team

  • Default avatar
    Khatereh Ahmadi
    CEO

    K Ahmadi, PhD MBA: Following a post-doc position at the Ludwig Institute for Cancer Research (UCL) she managed a drug discovery collaboration with Astellas Pharma, focused on cancer therapies. She was part of team that founded Piramed Ltd, where her achievements included a major alliance with Genentech and acquisition by Roche for 10x return for investors. She has been on management team of several biotech companies internationally.

  • Default avatar
    Stuart Cockerill
    CSO

    Dr. Cockerill has a Ph.D. in Organic Chemistry. After a Postdoc at Cornell University he joined the Wellcome Foundation and over the next 15 years contributed to and led drug discovery projects in Pesticides, Immunology, Virology and Oncology. His achievements include inventorship of Tykerb, marketed by GSK for breast cancer. Subsequently he joined Arrow Therapeutics where he and his team developed novel RSV therapeutics over a period of10 yrs

  • Default avatar
    Ken Powell
    Chairman

    Professor Powell, a successful entrepreneur in biotech: during his time at Wolfson Institute for Biomedical Research (UCL), He set up Inpharmatica (now part of Galapagos NV), Ark Therapeutics (now LSE listed) and Arrow Therapeutics. Ken led AT from its foundation in 1988 to a successful trade sale to Astra Zeneca in 2006 for $150M. With over 30 years‟ experience in the pharma/biotech business, Ken is a well respected figure in UK biotech industry